We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The use of anthracyclines in the treatment of endemic Burkitt lymphoma.
- Authors
Molyneux, Elizabeth; Schwalbe, Ed; Chagaluka, George; Banda, Kondwani; Israels, Trijn; Depani, Sarita; Mittermayer ‐ Vassallo, Kirstin; Windebank, Kevin; Mvula, Jessie; Njiram'madzi, Jenala; O'Brien, Stephen; Carey, Peter; Bailey, Simon
- Abstract
Burkitt lymphoma is the most common malignancy in children in Malawi, the world's poorest country, where there is a long history of treating this disease using a 28-day cyclophosphamide-based protocol. Stage III/ IV disease has had poor outcomes. In an attempt to improve the outcome for higher stage disease, anthracyclines were added to the existing protocol. The disease-free ( DFS) and overall survival ( OS) of 58 children with cytologically confirmed Burkitt lymphoma admitted during 2012-2014 and treated using this protocol were calculated. Six (10%) children had stage I disease, ten (17%) stage II and 42 stage III or IV (73%). Overall 12-month DFS ( OS) was 68·5% (72·9%); for stage I disease 100% (100%), stage II 56·2% (60%), stage III/ IV 66·3% (72·2%). The DFS was significantly improved from the previous protocol ( P = 8 × 10−4). The addition of doxorubicin to stage III and IV disease resulted in a markedly improved DFS. Anthracyclines are deliverable in resource-poor settings and possibly improve the survival of children with Burkitt lymphoma.
- Subjects
ANTHRACYCLINES; BURKITT'S lymphoma; ANTINEOPLASTIC antibiotics; EPSTEIN-Barr virus diseases; CHILDREN
- Publication
British Journal of Haematology, 2017, Vol 177, Issue 6, p984
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.14440